Analysts Estimate Catalyst Pharmaceutical (CPRX) to Report a Decline in Earnings: What to Look Out for

Company Overview - Catalyst Pharmaceutical (CPRX) is expected to report a year-over-year decline in earnings, with a projected earnings per share (EPS) of $0.42, reflecting a decrease of 40% compared to the previous year [3] - Revenues are anticipated to be $140.02 million, down 1.3% from the same quarter last year [3] Earnings Report Expectations - The earnings report is scheduled for release on February 25, and the actual results could significantly influence the stock price depending on whether they exceed or fall short of expectations [2] - The consensus EPS estimate has remained unchanged over the last 30 days, indicating a stable outlook from covering analysts [4] Earnings Surprise Prediction - The Most Accurate Estimate for Catalyst is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -47.93%, suggesting a bearish sentiment among analysts regarding the company's earnings prospects [11] - Despite the negative Earnings ESP, the stock holds a Zacks Rank of 3, making it challenging to predict a consensus EPS beat [11] Historical Performance - In the last reported quarter, Catalyst exceeded the expected EPS of $0.51 by delivering $0.68, resulting in a surprise of +33.33% [12] - Over the past four quarters, the company has consistently beaten consensus EPS estimates [13] Industry Context - Ionis Pharmaceuticals (IONS), another player in the Zacks Medical - Drugs industry, is expected to report a loss of $1.21 per share, indicating a year-over-year change of -83.3% [17] - Ionis's revenues are projected to be $155.58 million, down 31.5% from the previous year, but it has an Earnings ESP of +17.84%, suggesting a higher likelihood of beating the consensus EPS estimate [18][19]